Categories: News

Danaher Announces Conversion Date For Series A Mandatory Convertible Preferred Stock

WASHINGTON, April 12, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced today that its 4.75% Series A Mandatory Convertible Preferred Stock (the “Preferred Stock”), will automatically convert into shares of the Company’s Common Stock on April 15, 2022 (the “Conversion Date”). The conversion rate for each share of Preferred Stock will be 6.6632 shares of the Company’s Common Stock. Cash will be paid in lieu of fractional shares of Common Stock.

As previously announced, on April 15, 2022 holders of record at the close of business on March 31, 2022 will separately receive a final quarterly cash dividend of $11.875 per share on the Preferred Stock.

ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher’s globally diverse team of approximately 80,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life’s Potential. For more information, please visit www.danaher.com.

View original content:https://www.prnewswire.com/news-releases/danaher-announces-conversion-date-for-series-a-mandatory-convertible-preferred-stock-301524269.html

SOURCE Danaher Corporation

Staff

Recent Posts

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

2 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

2 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

2 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

2 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

2 hours ago

PulseAI Secures Seed Funding to Advance AI-Driven ECG Diagnostics

BELFAST, Northern Ireland  , Jan. 12, 2026 /PRNewswire/ -- PulseAI, a rapidly emerging leader in…

2 hours ago